Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.

Alzheimer's disease, AD, is the most common form of dementia. AD initially targets memory and progressively destroys the mind. The brain atrophies as the neocortex suffers neuronal, synaptic, and dendritic losses, and the hallmark amyloid plaques and neurofibrillary tangles proliferate. Pharmacological management, at best, is palliative and transiently effective, with marked adverse effects. Certain nutrients intrinsic to human biochemistry (orthomolecules) match or exceed pharmacological drug benefits in double-blind, randomized, controlled trials, with superior safety. Early intervention is feasible because its heritability is typically minimal and pathological deterioration is detectable years prior to diagnosis. The syndrome amnestic mild cognitive impairment exhibits AD pathology and to date has frustrated attempts at intervention. The condition age-associated memory impairment is a nonpathological extreme of normal brain aging, but with less severe cognitive impairment than amnestic mild cognitive impairment. Age-associated memory impairment is a feasible target for early intervention against AD, beginning with the modifiable AD risk factors - smoking, hypertension, homocysteine, type 2 diabetes, insulin resistance, and obesity. Stress reduction, avoidance of toxins, and mental and physical exercise are important aspects of prevention. The diet should emphasize omega-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid; flavonoids and other antioxidant nutrients; and B vitamins, especially folate, B6 and B12. Dietary supplementation is best focused on those proven from randomized, controlled trials: the phospholipids phosphatidylserine and glycerophosphocholine, the energy nutrient acetyl-L-carnitine, vitamins C and E, and other antioxidants. A comprehensive integrative strategy initiated early in cognitive decline is the most pragmatic approach to controlling progression to Alzheimer's disease.

[1]  P. Knipschild,et al.  The Efficacy of Ginkgo for Elderly People with Dementia and Age‐Associated Memory Impairment: New Results of a Randomized Clinical Trial , 2000, Journal of the American Geriatrics Society.

[2]  Carl W. Cotman,et al.  Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease , 2008, Neurobiology of Aging.

[3]  Kaarin J Anstey,et al.  Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. , 2007, American journal of epidemiology.

[4]  Parvesh Bubber,et al.  Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications , 2005, Annals of neurology.

[5]  Yaakov Stern,et al.  Mediterranean diet and Alzheimer disease mortality , 2007, Neurology.

[6]  A. Minagar,et al.  The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis , 2002, Journal of the Neurological Sciences.

[7]  F. Amenta,et al.  Nerve growth factor receptor immunoreactivity in the cerebellar cortex of aged rats: effect of choline alfoscerate treatment , 1993, Mechanisms of Ageing and Development.

[8]  J. Kaye,et al.  Blood–brain barrier impairment in Alzheimer disease , 2007, Neurology.

[9]  A. Nordberg Amyloid imaging in Alzheimer's disease , 2007, Current opinion in neurology.

[10]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[11]  L. Thal,et al.  Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease , 2003, International clinical psychopharmacology.

[12]  L. Thal,et al.  The Safety and Lack of Efficacy of Vinpocetine in Alzheimer's Disease , 1989, Journal of the American Geriatrics Society.

[13]  M. Fioravanti,et al.  Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. , 2005, The Cochrane database of systematic reviews.

[14]  L. Fernández-Novoa,et al.  Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. , 1999, Methods and findings in experimental and clinical pharmacology.

[15]  R. Hammersley,et al.  Health and neuropsychological functioning of dentists exposed to mercury , 2002, Occupational and environmental medicine.

[16]  C. Lyketsos,et al.  A clinical approach to mild cognitive impairment. , 2006, The American journal of psychiatry.

[17]  L. Fratiglioni,et al.  Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991, International journal of epidemiology.

[18]  C. Geula,et al.  Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study , 1989, Neuroscience.

[19]  J. Morris,et al.  Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. , 2005, Archives of neurology.

[20]  L. Thal,et al.  Smoking affects the phenotype of Alzheimer disease , 2005, Neurology.

[21]  W. Markesbery,et al.  Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. , 2000, The American journal of clinical nutrition.

[22]  D. Butterfield,et al.  Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment , 2007 .

[23]  B. Ames,et al.  gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. , 2001, The American journal of clinical nutrition.

[24]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[25]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[26]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[27]  M. Rapp,et al.  Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. , 2002, Pharmacopsychiatry.

[28]  W. Greenough,et al.  Usual vs. successful aging: Some notes on experiential factors , 1991, Neurobiology of Aging.

[29]  C. Burt,et al.  Glycerol phosphorylcholine (GPC) and serine ethanolamine phosphodiester (SEP): evolutionary mirrored metabolites and their potential metabolic roles. , 1994, Comparative biochemistry and physiology. Biochemistry and molecular biology.

[30]  J. Ringman,et al.  An experimental approach to detecting dementia in Down syndrome: A paradigm for Alzheimer’s disease , 2007, Brain and Cognition.

[31]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[32]  Richard J Kryscio,et al.  Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. , 2007, American journal of epidemiology.

[33]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[34]  R. Erasmus,et al.  The effect of stress on the antioxidative potential of serum: implications for Alzheimer’s disease , 2006, Metabolic Brain Disease.

[35]  J. Guralnik,et al.  Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias , 2000, Neurology.

[36]  J. Kaye,et al.  The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. , 1998, Archives of neurology.

[37]  Y. Hatefi The mitochondrial electron transport and oxidative phosphorylation system. , 1985, Annual review of biochemistry.

[38]  M. Tierney,et al.  Fatty acid analysis of blood plasma of patients with alzheimer's disease, other types of dementia, and cognitive impairment , 2000, Lipids.

[39]  W. Grant Accounting for Individual Differences in Risk of Alzheimer Disease , 2005, PLoS medicine.

[40]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[41]  R. Sapolsky Glucocorticoid toxicity in the hippocampus. Temporal aspects of synergy with kainic acid. , 1986, Neuroendocrinology.

[42]  J. Morris,et al.  Evidence That Age-Associated Memory Impairment Is Not a Normal Variant of Aging , 2001, Alzheimer disease and associated disorders.

[43]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[44]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[45]  Arthur F. Kramer,et al.  Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function , 2007, Trends in Cognitive Sciences.

[46]  T. Fulmer,et al.  Successful aging. , 2002, The American journal of nursing.

[47]  David O Carpenter,et al.  The role of metals in the etiology of Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[48]  Turan M. Itil,et al.  A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .

[49]  D. Allan Butterfield,et al.  Chapter 7 Protein Oxidation Processes in Aging Brain , 1997 .

[50]  K. Jellinger Head injury and dementia , 2004, Current opinion in neurology.

[51]  P. Mecocci,et al.  Antioxidants for the treatment of mild cognitive impairment , 2004, Neurological research.

[52]  A. Minihane,et al.  Dietary vitamin E modulates differential gene expression in the rat hippocampus: Potential implications for its neuroprotective properties , 2005, Nutritional neuroscience.

[53]  Andrew King,et al.  Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium , 2008, Brain pathology.

[54]  L. Thal,et al.  A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.

[55]  M. Gatz Educating the Brain to Avoid Dementia: Can Mental Exercise Prevent Alzheimer Disease? , 2005, PLoS medicine.

[56]  M. Traber,et al.  γ-Tocopherol, the new vitamin E? , 2003 .

[57]  N. Cairns,et al.  Thyroid stimulating hormone-receptor overexpression in brain of patients with Down syndrome and Alzheimer's disease. , 1999, Life sciences.

[58]  A. Hofman,et al.  Dietary Intake of Antioxidants and Risk of Alzheimer Disease , 2002 .

[59]  L. Marinangeli,et al.  Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration , 1993, Aging.

[60]  J. Hodges,et al.  Predicting Rapid Clinical Progression in Amnestic Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.

[61]  D. Marin,et al.  Variability of familial risk of Alzheimer disease across the late life span. , 2005, Archives of general psychiatry.

[62]  S. Ferris,et al.  Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work group , 1986 .

[63]  D. Bennett,et al.  Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study , 2022 .

[64]  L. Thal,et al.  Nerve growth factor promotes survival of new neurons in the adult hippocampus , 2007, Neurobiology of Disease.

[65]  K. Chien,et al.  Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. , 2007, Clinical therapeutics.

[66]  O. Napryeyenko,et al.  Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features , 2007, Arzneimittelforschung.

[67]  K. Ball,et al.  Long-term effects of cognitive training on everyday functional outcomes in older adults. , 2006, JAMA.

[68]  W. Haskell,et al.  Safety and efficacy of a ginkgo biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults. , 2007, Journal of the American Dietetic Association.

[69]  B. Winblad,et al.  Vitamin B12 and folate in relation to the development of Alzheimer’s disease , 2001, Neurology.

[70]  L. Schneider,et al.  Treatment and Care in Old Age Psychiatry , 1995 .

[71]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[72]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[73]  B. Christie,et al.  Antidepressant effects of exercise: evidence for an adult-neurogenesis hypothesis? , 2006, Journal of psychiatry & neuroscience : JPN.

[74]  R. Yokel Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. , 2006, Journal of Alzheimer's disease : JAD.

[75]  L. Parnetti,et al.  Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? , 2007, Journal of the Neurological Sciences.

[76]  A. Arshad,et al.  STATINS, INCIDENT ALZHEIMER DISEASE, CHANGE IN COGNITIVE FUNCTION, AND NEUROPATHOLOGY , 2008, Neurology.

[77]  P. Kidd,et al.  Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. , 2005, Alternative medicine review : a journal of clinical therapeutic.

[78]  P. Falkai,et al.  Traumatic brain injury: cause or risk of Alzheimer’s disease? A review of experimental studies , 2005, Journal of Neural Transmission.

[79]  J. Hardy,et al.  Has the amyloid cascade hypothesis for Alzheimer's disease been proved? , 2006, Current Alzheimer research.

[80]  A. Toga,et al.  Tracking Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[81]  P. Knipschild,et al.  Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. , 2003, Journal of clinical epidemiology.

[82]  C. Kawas Diet and the risk for Alzheimer's disease , 2006, Annals of neurology.

[83]  Kristine Yaffe,et al.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study , 2005, BMJ : British Medical Journal.

[84]  J. Cummings,et al.  Current and Emerging Pharmacological Treatment Options for Dementia , 2006, Behavioural neurology.

[85]  Alan L. Miller,et al.  The methionine-homocysteine cycle and its effects on cognitive diseases. , 2003, Alternative medicine review : a journal of clinical therapeutic.

[86]  N. Doidge The Brain That Changes Itself , 2007 .

[87]  A. Schatzberg,et al.  A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. , 1997, JAMA.

[88]  B. Ames,et al.  High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. , 2002, The American journal of clinical nutrition.

[89]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[90]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[91]  G. Patton,et al.  Low serum docosahexaenoic acid is a significant risk factor for alzheimer’s dementia , 2007, Lipids.

[92]  J. Yesavage,et al.  Effects of phosphatidylserine in age‐associated memory impairment , 1991, Neurology.

[93]  Robert M. Sapolsky,et al.  Why zebras don't get ulcers : an updated guide to stress, stress-related diseases, and coping , 1994 .

[94]  Jennifer L. Etnier,et al.  A meta-regression to examine the relationship between aerobic fitness and cognitive performance , 2006, Brain Research Reviews.

[95]  Li Wang,et al.  Exercise Is Associated with Reduced Risk for Incident Dementia among Persons 65 Years of Age and Older , 2006, Annals of Internal Medicine.

[96]  D. Guidolin,et al.  Behavioral and morpho-functional correlates of brain aging: a preclinical study with phosphatidylserine. , 1992, Advances in Experimental Medicine and Biology.

[97]  M. Beal,et al.  Mitochondrial dysfunction in neurodegenerative diseases. , 1998, Biochimica et biophysica acta.

[98]  B. Lawlor,et al.  Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study , 2003, British Journal of Nutrition.

[99]  W. Markesbery,et al.  Increased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease , 1998, Journal of neurochemistry.

[100]  R. Hoerr,et al.  Influence of the Severity of Cognitive Impairment on the Effect of the Ginkgo biloba Extract EGb 761® in Alzheimer’s Disease , 2002, Neuropsychobiology.

[101]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[102]  Charles Ramassamy,et al.  Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. , 2006, European journal of pharmacology.

[103]  Roy W Jones,et al.  Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? , 2003, International journal of geriatric psychiatry.

[104]  Sudha Seshadri,et al.  Homocysteine and cognitive performance in the Framingham offspring study: age is important. , 2005, American journal of epidemiology.

[105]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[106]  Yaakov Stern,et al.  Mediterranean diet and risk for Alzheimer's disease , 2006, Annals of neurology.

[107]  David Snowdon,et al.  Aging with Grace: What the Nun Study Teaches Us About Leading Longer, Healthier, and More Meaningful Lives , 2001 .

[108]  D. Butterfield,et al.  Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. , 2007, Free radical biology & medicine.

[109]  M. Moreno Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. , 2003 .

[110]  H. Möller,et al.  The case described by Alois Alzheimer in 1911 , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[111]  D. F. Swaab,et al.  Brain aging and Alzheimer's disease, “Wear and tear” versus “Use it or lose it” , 1991, Neurobiology of Aging.

[112]  C. Hulsebosch,et al.  Nerve growth factor binding in aged rat central nervous system: Effect of acetyl‐l‐carnitine , 1988, Journal of neuroscience research.

[113]  A. Convit,et al.  Cortisol levels during human aging predict hippocampal atrophy and memory deficits , 1998, Nature Neuroscience.

[114]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[115]  D. Kennedy,et al.  The psychopharmacology of European herbs with cognition-enhancing properties. , 2006, Current pharmaceutical design.

[116]  J. Palmblad,et al.  Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms , 2008, International journal of geriatric psychiatry.

[117]  Farzaneh A. Sorond,et al.  Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis , 2005, The Lancet Neurology.

[118]  Fred H. Gage,et al.  Adult neurogenesis , 2007, Scholarpedia.

[119]  C. Tseng,et al.  A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers , 2007, BMC neurology.

[120]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[121]  A. Kramer,et al.  Fitness Effects on the Cognitive Function of Older Adults , 2003, Psychological science.

[122]  P. S. St George-Hyslop,et al.  Prediction of probable Alzheimer's disease in memory-impaired patients , 1996, Neurology.

[123]  H. Lieberman,et al.  Citicoline improves verbal memory in aging. , 1996, Archives of neurology.

[124]  P. Bria,et al.  Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study , 2006, European journal of neurology.

[125]  P. Aisen,et al.  An update on huperzine A as a treatment for Alzheimer's disease , 2008, Expert opinion on investigational drugs.

[126]  P. Kidd,et al.  Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. , 2000, Alternative medicine review : a journal of clinical therapeutic.

[127]  P. Kidd,et al.  Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. , 2007, Alternative medicine review : a journal of clinical therapeutic.

[128]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[129]  L. Nadel,et al.  The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. , 2003, Child development.

[130]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[131]  A. Hofman,et al.  Thyroid hormones, dementia, and atrophy of the medial temporal lobe. , 2006, The Journal of clinical endocrinology and metabolism.

[132]  Y. Cai,et al.  Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. , 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[133]  H. Möller,et al.  Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. , 1998, Neurogenetics.

[134]  Gerd Kempermann,et al.  Physical exercise prevents age-related decline in precursor cell activity in the mouse dentate gyrus , 2006, Neurobiology of Aging.

[135]  J. Blass,et al.  Thiamine-dependent processes and treatment strategies in neurodegeneration. , 2007, Antioxidants & redox signaling.

[136]  D. Drachman Aging of the brain, entropy, and Alzheimer disease , 2006, Neurology.

[137]  K. Meador,et al.  Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type , 1993, Journal of geriatric psychiatry and neurology.

[138]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[139]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[140]  K. Yaffe,et al.  Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. , 2006, The journal of nutrition, health & aging.

[141]  R. Caselli,et al.  Current epidemiology of mild cognitive impairment and other predementia syndromes. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[142]  A. Hofman,et al.  Dietary fat intake and the risk of incident dementia in the Rotterdam study , 1997, Annals of neurology.

[143]  Caine W. Wong,et al.  Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome , 2002, Neuron.

[144]  Karl Herholz,et al.  PET studies in dementia , 2003, Annals of nuclear medicine.

[145]  J. Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.

[146]  R. Havlik,et al.  Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.

[147]  C. Patterson,et al.  Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease , 2008, Canadian Medical Association Journal.

[148]  P. Le Bars Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. , 2003, Pharmacopsychiatry.

[149]  R. Schmidt,et al.  Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study , 2002, Annals of neurology.

[150]  Walter Kukull,et al.  Progression to dementia in patients with isolated memory loss , 1997, The Lancet.

[151]  Robert M. Sapolsky,et al.  Why zebras don't get ulcers : a guide to stress, stress related diseases, and coping , 1994 .

[152]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[153]  D. Horrobin,et al.  Essential Fatty Acids in Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[154]  F. Amenta,et al.  Influence of ipsilateral lesions of the nucleus basalis magnocellularis and of choline alphoscerate treatment on histochemically reactive zinc stores and on the ultrastructure of the rat frontal cortex. , 1994, Archives of gerontology and geriatrics.

[155]  C. Pieper,et al.  The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype , 2006, Acta Neuropathologica.

[156]  D. Bennett,et al.  Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. , 2003, Archives of neurology.

[157]  G. Cole,et al.  The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease , 2007, Experimental Gerontology.

[158]  Deborah Gustafson,et al.  An 18-year follow-up of overweight and risk of Alzheimer disease. , 2003, Archives of internal medicine.

[159]  C. W. Tam,et al.  Screening of Mild Cognitive Impairment in Chinese Older Adults – A Multistage Validation of the Chinese Abbreviated Mild Cognitive Impairment Test , 2008, Neuroepidemiology.

[160]  L. Horrocks,et al.  Modulation of inflammation in brain: a matter of fat , 2006, Journal of neurochemistry.

[161]  Michael Meaney,et al.  Cortisol levels during human aging predict hippocampal atrophy and memory deficits , 1998, Nature Neuroscience.

[162]  D. Cucinotta,et al.  Posatirelin for the treatment of late‐onset Alzheimer's disease: a double‐blind multicentre study vs citicoline and ascorbic acid , 1995, Acta neurologica Scandinavica.